{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003355339,0.0003146404,0.002801831,0.0004163386,0.0001791355,0.00006395772,0.0006490671,0.0002711853,0.002087531],"category_scores_gemma":[0.0002038683,0.0001940339,0.0005494572,0.0004523582,0.0006231558,0.00007957287,0.0000755382,0.0007271996,0.00001622672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005337549,"about_ca_system_score_gemma":0.00161971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003147928,"about_ca_topic_score_gemma":0.006042316,"domain_scores_codex":[0.9963283,0.00104408,0.0008247164,0.0005159047,0.0005807994,0.0007062287],"domain_scores_gemma":[0.9968558,0.0008126576,0.0005652141,0.001271469,0.0003128403,0.0001820085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9646903,0.00142158,0.005973177,0.0000337782,0.002384654,0.0001748157,0.0008515592,0.0003357587,0.001191509,0.00003024781,0.0006175805,0.022295],"study_design_scores_gemma":[0.9722398,0.003379461,0.01651055,0.0001112117,0.001397625,0.00001241614,0.000111068,0.003751022,0.0008788596,0.00001810474,0.001397651,0.0001922651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741338,0.0007478594,0.00006236865,0.01482136,0.0003595762,0.006044703,0.0003165673,0.00002645762,0.003487291],"genre_scores_gemma":[0.991768,0.0007480829,0.0001138935,0.001213784,0.001387792,0.004362972,0.00004373377,0.00004102296,0.0003206895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02210273,"threshold_uncertainty_score":0.9988247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09916280515671266,"score_gpt":0.4624950642930083,"score_spread":0.3633322591362956,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}